De Novo device
FEops HEARTguide Simulation Application
Feops NV · Interventional Cardiovascular Implant Simulation Software Device (QQI, Class II) · First FDA decision Sep 8, 2021, newest Nov 25, 2025Aortic stenosis
Last checked: Nov 19, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
3
De Novo pathway
Device trials
0
Naming "FEops HEARTguide"
MAUDE reports
0
Brand "FEops HEARTguide", since 2015
PubMed studies
16
Mentioning "FEops HEARTguide"
AI summary across all sources
Written by Claude (Anthropic's AI) from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
FDA decisions
The newest 3 of 3 decisions filed under this name.
K250635 · Decided Nov 25, 2025 · 267 days after receipt
Device type: Interventional Cardiovascular Implant Simulation Software Device (QQI) · Cardiology
- FEops HEARTguide510(k)
K214066 · Decided Feb 25, 2022 · 60 days after receipt
Device type: Interventional Cardiovascular Implant Simulation Software Device (QQI) · Cardiology
- FEops HEARTguideNew device typeDe Novo
DEN200030 · Decided Sep 8, 2021 · 489 days after receipt
Device type: Interventional Cardiovascular Implant Simulation Software Device (QQI) · Cardiology
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
No Medicare coverage document has a title matching this device or device type. Many devices are paid under existing codes without one.
Clinical trials
Device studies on ClinicalTrials.gov that name "FEops HEARTguide", any status and sponsor, newest update first.
No registered device study names "FEops HEARTguide".
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "FEops HEARTguide", and for the whole product code for context.
This brand
0 reports: 0 malfunction, 0 injury, 0 death
Whole product code QQI
0 reports: 0 malfunction, 0 injury, 0 death
Newest reports for this brand
No MAUDE reports name this brand.
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "FEops HEARTguide"[tiab]. The summary above synthesizes these.
- FEops HEARTguide Patient-Specific Computational Simulations for WATCHMAN FLX Left Atrial Appendage Closure: A Retrospective Study.
Ranard LS, Vahl TP, Sommer R, et al. · JACC Adv · 2022
- Clinical Validation of Predictive Procedural Planning Software in a Real-World TAVI Population.
Claes AS, Paelinck B, Rodrigus I, et al. · Catheter Cardiovasc Interv · 2025Validation Study, Comparative Study
- Clinical value of CT-derived simulations of transcatheter-aortic-valve-implantation in challenging anatomies the PRECISE-TAVI trial.
Hokken TW, Wienemann H, Dargan J, et al. · Catheter Cardiovasc Interv · 2023Observational Study, Multicenter Study
- Clinical Value of CT-Based 3D Computational Modeling in Left Atrial Appendage Occlusion: An In-Depth Analysis of the PRECISE LAAO Study.
De Cock E, Lochy S, Rivero-Ayerza M, et al. · Catheter Cardiovasc Interv · 2025Multicenter Study, Research Support, Non-U.S. Gov't
- CT-derived simulations to predict outcomes in patients undergoing transcatheter aortic valve implantation with an ACURATE Neo2 valve the PRECISE-TAVI cohort B trial.
Hokken TW, Nuyens P, Ruffo C, et al. · Catheter Cardiovasc Interv · 2024Multicenter Study, Observational Study
- Left atrial appendage closure guided by fusion of 3D computational modelling on real-time fluoroscopy: A multicenter experience.
Garot P, Gall E, Zendjebil S, et al. · Int J Cardiol · 2025Multicenter Study
- Value of FEops HEARTguide patient-specific computational simulations in the planning of left atrial appendage closure with the Amplatzer Amulet closure device: rationale and design of the PREDICT-LAA study.
Garot P, Iriart X, Aminian A, et al. · Open Heart · 2020Clinical Trial Protocol, Research Support, Non-U.S. Gov't
- Sealing Behavior in Transcatheter Bicuspid and Tricuspid Aortic Valves Replacement Through Patient-Specific Computational Modeling.
Liu X, Fan J, Mortier P, et al. · Front Cardiovasc Med · 2021
- Computer simulation help predict the frame deformation following a Venus-A transcatheter aortic valve implantation in patients with pure aortic regurgitation: a retrospective study.
Yu F, Chen S, Tian L, et al. · Cardiovasc Diagn Ther · 2024
- Percutaneous closure of a 'whale tail' left atrial appendage with a Watchman FLX device and pre-procedural FEops HEARTguide patient-specific computational simulation: a case report.
Di Muro FM, Stolcova M, Di Mario C, et al. · Eur Heart J Case Rep · 2022Case Reports
- Preoperative computed tomography-imaging with patient-specific computer simulation in transcatheter aortic valve implantation: Design and rationale of the GUIDE-TAVI trial.
Hegeman RRMJJ, van Ginkel DJ, Laengle S, et al. · Am Heart J · 2024Research Support, Non-U.S. Gov't, Clinical Trial Protocol
- Transcatheter aortic valve replacement: impact of pre-procedural FEops HEARTguide assessment on device size selection in borderline annulus size cases.
Halim J, Brouwer J, Lycke M, et al. · Neth Heart J · 2021
Other devices of this type
Also filed under product code QQI.
- PrecisionTAVI (v1.1)Dasi Simulations · 510(k) 2023
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.